ReviewFrontiers in neuroscience2023
Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma.
Review in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.Neuroendocrinology · 2026Article
- Challenging the known: unusual case report of acromegaly and subclinical Cushing's disease combination.AME case reports · 2026Article
- The Triple Hormone Enigma: Pituitary Macroadenoma With Bilateral Cortisol-Androgen Secreting Adenomas.JCEM case reports · 2025Article
- Impact of potential biomarkers, SNRPE, COX7C, and RPS27, on idiopathic Parkinson's disease.Genes & genomics · 2025Article
- Intracranial neuroendocrine carcinoma with coexisting pituitary adenoma: a case report and comprehensive literature review.Frontiers in oncology · 2025Article
- Signal Transducer and Activator of Transcription 4 (STAT4) Association with Pituitary Adenoma.Medicina (Kaunas, Lithuania) · 2024Article
- The current state of MRI-based radiomics in pituitary adenoma: promising but challenging.Frontiers in endocrinology · 2024Review
- Editorial: Prognostic factors in pituitary tumors: clinical, biochemical, imaging, and pathological aspects.Frontiers in endocrinology · 2024Article
- Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plurihormonal pituitary adenoma (PPA) is a type of pituitary tumor capable of producing two or more hormones and usually presents as an aggressive, large adenoma. As yet, its pathogenesis remains unclear. This is the first study to systematically summarize the underlying pathogenesis of PPA. The pathogenesis is related to plurihormonal primordial stem cells, co-transcription factors, hormone co-expression, differential gene expression, and cell transdifferentiation. We conducted a literature review of PPA and analyzed its clinical characteristics. We found that the average age of patients with PPA was approximately 40 years, and most showed only one clinical symptom. The most common manifestation was acromegaly. Currently, PPA is treated with surgical resection. However, recent studies suggest that immunotherapy may be a potentially effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.